Cormorant Asset Management’s Sage Therapeutics SAGE Stock Holding History

Cormorant Asset Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-88,700	Closed	-$12.4M	–	77
2019 Q3	$12.4M	Sell	88,700 -11,300	-11%	-$1.89M	0.76%	39
2019 Q2	$18.3M	Sell	100,000 -30,000	-23%	-$5.12M	1.05%	32
2019 Q1	$20.7M	Sell	130,000 -53,732	-29%	-$7.78M	1.4%	27
2018 Q4	$17.6M	Sell	183,732 -6,268	-3%	-$717K	1.43%	27
2018 Q3	$26.8M	Sell	190,000 -49,619	-21%	-$7.66M	1.74%	22
2018 Q2	$37.5M	Hold	239,619	–	–	2.78%	11
2018 Q1	$38.6M	Buy	+239,619	New	+$40.7M	2.88%	8
2016 Q3	–	Sell	-730,000	Closed	-$22M	–	90
2016 Q2	$22M	Sell	730,000 -215,000	-23%	-$7.17M	3.12%	8
2016 Q1	$30.3M	Buy	945,000 +630,000	+200%	+$22.2M	4.56%	3
2015 Q4	$18.4M	Buy	315,000 +75,000	+31%	+$3.72M	2.2%	12
2015 Q3	$10.2M	Buy	+240,000	New	+$14.8M	1.62%	21
2015 Q2	–	Sell	-850	Closed	-$43K	–	84
2015 Q1	$43K	Sell	850 -150	-15%	-$6.45K	0.01%	71
2014 Q4	$37K	Sell	1,000 -9,000	-90%	-$335K	0.01%	70
2014 Q3	$315K	Buy	+10,000	New	+$290K	0.06%	65

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Cormorant Asset Management's SAGE Position: Q4 2019 in Review

Cormorant Asset Management sold out of Sage Therapeutics (SAGE) in Q4 2019, closing a stake of 88,700 shares — an estimated $12.4M sold.

Cormorant Asset Management first reported a position in SAGE in Q3 2014 and held it in 14 quarters. The position peaked at $38.6M in Q1 2018. 267 funds tracked by Wall St. Rank hold SAGE as of Q4 2019.

Cormorant Asset Management reported no remaining Sage Therapeutics position as of Q4 2019 after selling out during the quarter.
Cormorant Asset Management sold 88,700 Sage Therapeutics shares in Q4 2019, an estimated $12.4M.
Cormorant Asset Management first reported a position in Sage Therapeutics in Q3 2014 and held it in 14 quarters.
Cormorant Asset Management's Sage Therapeutics position peaked at $38.6M in Q1 2018.
267 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2019.

Based on Cormorant Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.